The majority of anticancer drugs have poor aqueous solubility, produce adverse effects in
healthy tissue, and thus impose major limitations on both clinical efficacy and therapeutic …

Glioblastoma, the most common, aggressive brain tumor, ranks among the least curable
cancers—owing to its strong tendency for intracranial dissemination, high proliferation potential, …

Cytotoxic effects of chemotherapy and radiation therapy (RT) used for the treatment of brain
metastases results from DNA damage within cancer cells. Cells rely on highly evolved DNA …

Although doxorubicin (dox), an anthracycline antibiotic, is widely used and effective in
treating cancer, its treatment efficiency is limited by low blood plasma solubility, poor …

The effective treatment of brain tumors is a considerable challenge in part because of the
presence of the blood-brain barrier (BBB) that limits drug delivery. Glioblastoma multiforme (…

Glioblastoma (GBM) is a primary brain tumor that carries a dismal prognosis, which is primarily
attributed to tumor recurrence after surgery and resistance to chemotherapy. Since the …

To increase treatment efficiency for glioblastoma, we have developed a system to selectively
deliver chemotherapeutic doxorubicin (Dox) to Glioblastoma (GBM) tumors. This carrier is …

Genotoxic damage induced by radiation triggers a highly coordinated DNA damage
response, and molecular inhibitors of key nodes within this complex response network can …

Background EGFR targeting antibody-drug conjugates (ADCs) are highly effective against
EGFR-amplified tumors, but poor distribution across the blood–brain barrier (BBB) limits their …

The application of rationally designed therapeutic peptides (TP) may improve outcomes in
cancer treatment. These peptides hold the potential to directly target proliferative pathways …